Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's "radical" changes.

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...

The Greeks who hold the keys to JP Morgan Chase, Costco, Pfizer, Fendi, Duke Energy, the banker who saved the US economy in ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

“Listen to what President Trump has to say and act accordingly,” Finnish President Alexander Stubb said in an interview. “A country like Finland will certainly do that.” Some were more playful. “If ...

Among the executive order's directives, companies were required to report details of their technology to federal regulators. Separately, Doctors Without Borders, physicians, and industry top brass ...